 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- anti-BCMA CAR T cells (T-cells targeting B-cell maturation antigen) / National Cancer Institute, anti-GD2 chimeric antigen receptor T cell therapy / Bellicum, National Cancer Institute, CD22-CAR T cell therapy / National Cancer Institute
Infectious Complications Associated with CAR T-Cell Therapy (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6199;
Our study demonstrates that adult age, prior history of infection, increased number of prior therapies and enrollment on a particular CAR T-cell trial, in this case the CD22 CAR-T trial, may lead to a higher risk of infection than in those without these risk factors . Further investigations are underway to evaluate clinical outcomes with infection which occur in the peri CAR T-cell setting and potential strategies to minimize infection risk .
- anti-GD2 CAR-T cell therapy / Bellicum, National Cancer Institute
Trial completion, Enrollment change, IO biomarker: 14-C-0059: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (clinicaltrials.gov) - Feb 2, 2017
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Further investigations are underway to evaluate clinical outcomes with infection which occur in the peri CAR T-cell setting and potential strategies to minimize infection risk . Recruiting --> Completed | N=72 --> 15
- anti-GD2 CAR-T cell therapy / Bellicum, National Cancer Institute
Trial primary completion date, IO biomarker: 14-C-0059: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (clinicaltrials.gov) - Aug 21, 2014
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=72 --> 15 Trial primary completion date: Dec 2016 --> Mar 2017
- anti-GD2 CAR-T cell therapy / Bellicum, National Cancer Institute
New P1 trial, IO biomarker: 14-C-0059: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (clinicaltrials.gov) - Apr 7, 2014
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
- anti-GD2 CAR-T cell therapy / Bellicum, National Cancer Institute
Enrollment open, IO biomarker: 14-C-0059: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (clinicaltrials.gov) - Apr 4, 2014
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Mar 2017 Not yet recruiting --> Recruiting